Related Experiment Video
Updated: Apr 18, 2026

Detection of Small GTPase Prenylation and GTP Binding Using Membrane Fractionation and GTPase-linked Immunosorbent Assay
Published on: November 11, 2018
The rapid lipopolysaccharide-induced release of matrix metalloproteinases 9 is suppressed by simvastatin
Dan-Dong Li1, Hong-Gang Pang1, Jin-Ning Song1
1Department of Neurosurgery, the First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Abstract:
A rapid increase in matrix metalloproteinase-9 (MMP-9) expression by stimulated leukocytes is common in many diseases. Recent evidence suggests that the beneficial effects of statins are mediated in part by the suppression of MMP-9 release. In this study, we investigated the effect of statin on MMP-9 expression and its antagonist, tissue inhibitor of metalloproteinase-1 (TIMP-1) in LPS-stimulated leukocytes. Rat neutrophils and monocytes were stimulated with lipopolysaccharide (LPS) in the presence of simvastatin. MMP-9 secretion and mRNA expression were analyzed using ELISA and RT-PCR, respectively. Total MMP-9 protein production was measured by Western blot analysis. Potential signal transduction pathways responsible for MMP-9 production were investigated using luciferase reporter assays (NF-κB), pull-down assays (RhoA), and pharmacological inhibition. Our data show that MMP-9 and TIMP-1 expression are differentially induced by LPS in neutrophils and monocytes. We showed that rapid MMP-9 release occurred mainly via secretion from intracellular stores. Moreover, we showed that statin significantly suppressed LPS-induced MMP-9 release and mRNA expression in a time- and concentration-dependent manner. We also evaluated that simvastain postponed the rapid LPS-induced MMP-9 release for about 20 min. In conclusion, we demonstrated that the suppressive effect of simvastatin on LPS-stimulated MMP-9 release does not occur via the NF-κB pathway and the MAPKs pathway, but via the RhoA/ROCK pathway.
Insights
Statins, like simvastatin, significantly reduce matrix metalloproteinase-9 (MMP-9) release from stimulated leukocytes. This suppression occurs via the RhoA/ROCK pathway, not NF-κB or MAPKs.
Area of Science:
- Immunology
- Pharmacology
Background:
- Matrix metalloproteinase-9 (MMP-9) is upregulated in many diseases.
- Statins may exert beneficial effects by suppressing MMP-9.
Purpose of the Study:
- To investigate simvastatin's effect on MMP-9 and TIMP-1 in lipopolysaccharide (LPS)-stimulated rat leukocytes.
- To elucidate the signaling pathways involved in MMP-9 regulation by statins.
Main Methods:
- Leukocytes (neutrophils, monocytes) stimulated with LPS and simvastatin.
- Assessed MMP-9 secretion (ELISA), mRNA (RT-PCR), and protein (Western blot).
- Investigated signaling pathways using luciferase assays (NF-κB), pull-down assays (RhoA), and inhibitors.
Main Results:
- LPS differentially induced MMP-9 and TIMP-1 in neutrophils and monocytes.
- MMP-9 release primarily occurred via secretion from intracellular stores.
- Simvastatin significantly suppressed LPS-induced MMP-9 release and mRNA expression in a time- and dose-dependent manner, delaying release by ~20 min.
- Statin's suppressive effect on MMP-9 was mediated via the RhoA/ROCK pathway, independent of NF-κB and MAPKs.
Conclusions:
- Simvastatin effectively suppresses LPS-induced MMP-9 release and expression in leukocytes.
- The RhoA/ROCK pathway is the primary mediator of simvastatin's inhibitory effect on MMP-9, distinct from NF-κB and MAPK pathways.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Role of Matrix Metalloproteases in Degradation of ECM